Plunkett Research Online: Y-mAbs Therapeutics Inc

Y-MABS THERAPEUTICS INC (YMAB:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Its pipeline covers Naxitamab, Omburtamab, GD2-GD3 Vaccine, and others......



Y-mAbs Therapeutics Inc
Ticker: YMAB
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 646 885-8505
Fax:
Address: 230 Park Avenue
Suite 3350
New York, NY 10169 United States

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceutical Preparation Manufacturing
Contacts Description
Michael RossiCEO/Director/President
Peter PfreundschuhCFO/Treasurer
See More
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Its pipeline covers Naxitamab, Omburtamab, GD2-GD3 Vaccine, and others......See More See More

Auditor: PricewaterhouseCoopers LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
202320222021202020192018
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
NameTitleSalary (US$)Bonus (US$)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: